 | | Vol. 4.46 – 4 December, 2020 |
| |
|
|
| Using genetic, proteomic and pharmacological approaches, the authors identified the aminotransferases and specifically Agxt as effectors of the suppressor function of Lkb1 in amino acid-driven gluconeogenesis.
[Nature Communications] |
|
 |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Hepatic progenitor cells either derived in microfluidics or exposed to exogenous ECM stimuli showed a significantly higher potential of forming hepatic organoids that could be rapidly expanded for several passages and further differentiated into functional hepatocytes.
[Cell Reports] |
|
|
|
| Investigators demonstrated here that hypoxia significantly attenuated sensitivity of hepatocellular carcinoma (HCC) cells to sorafenib treatment and reduced its proliferation. Autophagy was observed in sorafenib-treated HCC cells in hypoxia, and inhibition of autophagy by 3-MA eliminated hypoxia-induced sorafenib resistance.
[Cell Death & Disease] |
|
|
|
| Expression of miR-451a and a disintegrin and metalloprotease 10 in hepatocellular carcinoma tissues and adjacent normal tissues was determined. The exosomes were extracted from human umbilical cord mesenchymal stem cells and co-cultured with Hep3B and SMMC-7721 cell lines.
[RNA Biology] |
|
|
|
| The impact of ECM on TGF-β-mediated fibrogenic signaling pathway in hepatic stellate cells (HSCs) has remained obscure. Investigators studied the role of non-receptor tyrosine kinase focal adhesion kinase family members in TGF-β-signaling in HSCs.
[Scientific Reports] |
|
|
|
| Expression levels of molecules involved in cellular signaling such as AMPK pathway, TGF-β family pathway, and MAP kinase pathway were decreased by FeCl3 treatment in rat primary hepatocytes. Cell viability in response to FeCl3 treatment was decreased in RPH but not in HepG2 and Hepa1-6 cells.
[Scientific Reports] |
|
|
|
| Scientists attempted to investigate the potential role of miR-9-5p in the progression of hepatocellular carcinoma (HCC). Expression of pyruvate dehydrogenase kinase 4 and miR-9-5p was examined in HCC tissues collected from HCC patients and cell lines.
[Cancer Gene Therapy] |
|
|
|
| Researchers knocked down lncRNA DLX6-AS1 and manipulated the expression of miR-513c to characterize their effects in hepatocellular carcinoma cell viability, migration, invasion, and apoptosis.
[Cancer Gene Therapy] |
|
 |
|
|
|
| The authors review the roles of multiple immunological mechanisms and therapeutic targets related to the inflammation associated with fatty liver diseases and the differences in the progression of alcoholic liver disease and nonalcoholic fatty liver disease. Multiple cell types in the liver, including macrophages, neutrophils, other immune cell types and hepatocytes, are involved in fatty liver disease inflammation.
[Cellular & Molecular Immunology] |
|
|
|
| Investigators review the latest achievements related to methionine metabolism and CLD, from molecular mechanisms to clinical research, and provide some insights into the future direction of basic and clinical research.
[Signal Transduction and Targeted Therapy] |
|
|
|
|
| CytoDyn, Inc. announced the first patient first visit metric was met for the company’s Phase II clinical trial for the treatment of nonalcoholic steatohepatitis (NASH). The Phase II trial is designed to test whether leronlimab may inhibit the devastating liver fibrosis associated with NASH.
[CytoDyn, Inc.] |
|
|
|
| BridgeBio Pharma, Inc. and affiliate QED Therapeutics announced that the FDA has accepted their New Drug Application for infigratinib, an oral FGFR1-3 selective inhibitor, for individuals with cholangiocarcinoma, or cancer of the bile ducts.
[BridgeBio Pharma, Inc.] |
|
|
|
|
| June 23 – June 26, 2021
Hamburg, Germany |
|
|
|
|
|
| | University of Cincinnati – Cincinnati, Ohio, United States |
|
|
|
| | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | Karolinska Institutet – Stockholm, Sweden |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
| | University of Michigan – Ann Arbor, Michigan, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
